Cardiovascular Systems

Cardiovascular Systems Equity

Delisted

The The Equity of Cardiovascular Systems (CSII) as of Nov 16, 2026 is 249.48 M USD. In the previous year, The Equity was 270.96 M USD — a change of -7.93% (lower).

Equity

249.48 MUSD

YoY

-7.93%

Last updated:

In 2022, Cardiovascular Systems's equity was 249.48 M USD, a -7.93% increase from the 270.96 M USD equity in the previous year.

The Cardiovascular Systems Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
139.44 M USD
Jan 1, 2016
100.90 M USD
Jan 1, 2017
118.39 M USD
Jan 1, 2018
134.47 M USD
Jan 1, 2019
147.94 M USD
Jan 1, 2020
268.79 M USD
Jan 1, 2021
270.96 M USD
Jan 1, 2022
249.48 M USD
The Cardiovascular Systems Equity history
YEAREquityYoY
249.48 MUSD-7.93%
270.96 MUSD+0.81%
268.79 MUSD+81.68%
147.94 MUSD+10.02%
134.47 MUSD+13.58%
118.39 MUSD+17.34%
100.90 MUSD-27.64%
139.44 MUSD-8.30%
152.06 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardiovascular Systems Stock analysis

What does Cardiovascular Systems do? Cardiovascular Systems Inc. (CSI) is a US medical technology company founded in 1989. The company is headquartered in St. Paul, Minnesota and employs approximately 1,000 employees worldwide. CSI develops, manufactures, and distributes innovative devices for the treatment of vascular diseases. The business model of CSI is based on the development and marketing of medical devices for minimally invasive treatment of vascular diseases. The company generates a significant portion of its revenues through the sale of its products to hospitals and specialized healthcare facilities. Additionally, CSI also offers training and educational programs for doctors and medical personnel to optimize the use of their devices. CSI operates in two main segments: peripheral arterial disease (PAD) and coronary heart disease (CHD). The PAD segment includes devices for the treatment of vascular diseases outside of the heart, such as peripheral arterial occlusive disease (PAOD). This includes the Diamondback-360® catheter and the Stealth 360® catheter, both used for plaque ablation in the arteries. The CHD segment focuses on the treatment of heart diseases such as coronary artery disease (CAD). This includes the Orbital Atherectomy System (OAS), a device that can reduce the use of stents in patients with more severe coronary artery narrowings. CSI's core product is the Diamondback-360® catheter, which was approved by the US Food and Drug Administration (FDA) in 2013. This device consists of a rotating catheter inserted into the artery to remove plaque causing vessel narrowing. The Diamondback-360 catheter is used for the treatment of PAD and has the potential to significantly improve patients' quality of life. Another important product from CSI is the Orbital Atherectomy System (OAS), used for the treatment of CAD. The OAS system is a rotating catheter that can remove plaque in the coronary arteries to improve blood flow. The use of OAS can potentially avoid costly and invasive procedures such as coronary angiography or bypass. In summary, Cardiovascular Systems Inc. is a leading company in the development and production of innovative devices for minimally invasive treatment of vascular diseases. The company specializes in two main segments, peripheral arterial disease and coronary heart disease. With products like the Diamondback-360 catheter and the Orbital Atherectomy System, CSI has established itself as a reliable provider of high-quality medical devices. Through training and educational programs, CSI also contributes to improving medical care and the development of treatment methods. Cardiovascular Systems is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cardiovascular Systems's Equity

Cardiovascular Systems's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cardiovascular Systems's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cardiovascular Systems's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cardiovascular Systems's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cardiovascular Systems’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cardiovascular Systems stock

The Equity of Cardiovascular Systems is 249.48 M USD in 2022.

The Equity of Cardiovascular Systems changed from 270.96 M USD to 249.48 M USD, representing a -7.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cardiovascular Systems since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cardiovascular Systems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cardiovascular Systems

All Key Metrics — Cardiovascular Systems